Advertisement
Canada markets open in 1 hour 26 minutes
  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • DOW

    37,775.38
    +22.07 (+0.06%)
     
  • CAD/USD

    0.7265
    +0.0001 (+0.02%)
     
  • CRUDE OIL

    82.35
    -0.38 (-0.46%)
     
  • Bitcoin CAD

    89,297.35
    +3,010.85 (+3.49%)
     
  • CMC Crypto 200

    1,342.97
    +30.35 (+2.37%)
     
  • GOLD FUTURES

    2,393.00
    -5.00 (-0.21%)
     
  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     
  • 10-Yr Bond

    4.6470
    0.0000 (0.00%)
     
  • NASDAQ futures

    17,476.00
    -71.25 (-0.41%)
     
  • VOLATILITY

    18.82
    +0.82 (+4.56%)
     
  • FTSE

    7,837.66
    -39.39 (-0.50%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • CAD/EUR

    0.6818
    -0.0003 (-0.04%)
     

Stocks in play: Immunovaccine Inc.

Announced positive top-line clinical data from its ongoing Phase 1b trial evaluating the safety and ...

Announced positive top-line clinical data from its ongoing Phase 1b trial evaluating the safety and efficacy of Immunovaccine’s lead immuno-oncology candidate, DPX-Survivac, in combination with Incyte’s IDO1 enzyme inhibitor epacadostat, and low-dose cyclophosphamide in patients with advanced ovarian cancer. Immunovaccine is conducting the trial in a collaboration with Incyte Corporation. Immunovaccine Inc.